CARE1 by Laurence Albiges
CARE1: A European Study on FirstLine Treatment of Metastatic Kidney Cancer. CARE1 is a European project coordinated by Gustave Roussy, initiated on May 1st, 2023. Focused on pragmatic clinical trials, it aims to improve the firstline treatment for patients with metastatic kidney cancer by implementing a routine biomarker, leveraging a unique academic network in Europe. In 2020, Europe saw over 138, 000 new cases of clear cell renal carcinoma, the most common form of kidney cancer, resulting in 50, 000 deaths (source: GLOBOCAN). To define research priorities in academia and launch dedicated clinical trials for this tumor, European oncologists have joined forces under the CARE group. This consortium brings together 14 partners, including four from Cancer Core Europe, representing 8 European countries (France, Germany, Spain, the Netherlands, Italy, Austria, the Czech Republic, and the United Kingdom). CARE1 also includes two patient associations. Its goal is to assist oncologists in selecti
|